PT91191B - Processo para a lactonizacao de acidos mevinicos e seus analogos - Google Patents

Processo para a lactonizacao de acidos mevinicos e seus analogos Download PDF

Info

Publication number
PT91191B
PT91191B PT91191A PT9119189A PT91191B PT 91191 B PT91191 B PT 91191B PT 91191 A PT91191 A PT 91191A PT 9119189 A PT9119189 A PT 9119189A PT 91191 B PT91191 B PT 91191B
Authority
PT
Portugal
Prior art keywords
process according
compound
alkyl
acid
quot
Prior art date
Application number
PT91191A
Other languages
English (en)
Other versions
PT91191A (pt
Inventor
Laszlo R Treiber
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22827965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT91191(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PT91191A publication Critical patent/PT91191A/pt
Publication of PT91191B publication Critical patent/PT91191B/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Description

. ι i - : 1-:-, 1 'τ
ς:-· + t-::· "::: .. ^ .j , .£ 1 - .· :;η η: .Π t. é ti O-i ·!" Λ~ Γ ··' Ζ’ 'J. 1 Γ; Cc' 5
HOY^co2á *»
R d A é h i d~ g ::u bu 11 tu:, d o fenilo, diííí í_! -? ' 1 gru ir*
bad original \
s.né.locz-s & sono o n 1 oa ou 1001-si η uá t .1. cos condui a uma nisiuio daa-fo-;:uv lactona e ácido d 1 f. i d 1 c u i „ nõv-o.cor!' o conircidliiido nu ..ίο má c.od 1 Ocierói do alio ren diuento ouro o. 11 c cor: i c uç do do livre ou 00.I amónio foi ofectuada colo ucuoc inon ío cosòoo cuba-
1 U : - 1' 1 O. : Π .· · O O: l - 0 1 dO 10' 0 ,0 10,..: , · O_i. _ c\ ~ _ :: - - - “V õiilij, ou acetato ísluo-ddiIicg a, ou. ::ué o i mo do rafluuo, A lac f'oo ia;á j õ o o ta 1 i c a:du cola prosoroí do· ilidi. A acidioidado
bad original
·> - .- - ol! ·· · .· ao :a.::3.:; a. a a a. d;,; da ua aaid- f i lavada do prado do:· I a a : ::r· a alaora 'a invar ter o acoA I iiaaa a-ara a voa.sa a.:- ; --1:--- ri i h 1 H •iov sal e=o | ,q - 3 a; : _ _1 1 -]- . __ : — · . de • ·· . _ · a,aa a a _ loc 3 ,z ee - e e . e-~e 3 a . a. - a.v-aioa aa o:a-r a da:, lid pela '-eao :: da: a: a o d· —prado a a o da a : ; a a : -Hv, , 0.0-0 La .· □ d ãLLL.· Γ- r ea,g en t a ãã.·- ãalã d- des 11 1 .? e S’ c· a· :e: orai;;:a a. d d. ea oabogaa ao O. d Oi t G ·, A ;- aa.ddaa da do-a, a Γ· :· V V A! da aal a raio ia— a cauiinie inve i- r e C DG3 i c da do equilíbrio paea o l.adc lãctcna . Π- ·" i ’ cr: -ãdCd e c a Lrdariaraa ,a Ξ C' ' r.Ã ffi - -½ dlã; CC ·' C "= * ã 3 ene, T i p iere ata o dada draaba de aa:.da : v. :d Όνο a·:: ee-< cecc- c c a d a 1 i. o a o a r ácid d r aaa,; a '-- p lí a n t ο ο o: j. o a d.' a. r ta f:L ··· >Λ Lee:, cp.jd de ,·- o a a ;?q d - a j.ij i ξ e e d e .a..;. ::aaa booaaa: de . · · e para i t i ndo a foríiícd· aaaoãõ.ida da aub—a ada- actana e x. __ ·_ ;.J z> * Sob a a d do d i. ç das da rsa.Cidlu, α produto 3 -hidra-a i 1 e - íad ado durão te oericdc'5 do tesnpc· pre 1 r-ngade-s ao á o id o qae r d o d u d a d u a a t i d a ci e s crasLanteã da dioarc i. ' o qu.a ds l: :v, raacc?: de ea t er i f i a ac ao entra o graoe 3-hidro/i 1c da 3-da. d raa i. acdona e o á ai do Iivre„ r—- -— -------
$AD ORlGfNAL
Uma segunda impureza, t-enul tente d a desidra taç^o do grupo 3-hidrc;; i. I α no anel lactanj , fce também ciu-sr· ado Líand:; condicSes de I actoni zaçao ar. ter i ores» Eso? impureza foi do τι esmo modosa inef i.c ien ieoen te removida poso reooòsta! loaoSo, originardí: menores rendi men tos. 0 preser, te invento alivia esto problema..
BAD ORIGINAL
o» -a ca. ar ti τ ca caio :\a rca ;< n a: η d a ο o ç3c completa da 1 aciona r lacto ri a. a conduz aos lo è. czncletíÇno da rir-n:z:-ac, a lactona a cor tinuansir do· rsm loco que se forma, minimizando a &;;dcci riu. da raa.op ΐο a min imoz ar zio aooim reaccao coaierior dscs formar dmmeroo., 1 : -· - Z O p ?- ' .· . lado d nizaçao, No prezar; i ;;io naco os reaceu a 1 a c. teria ·· c C Ο Γ: d .1. -~ z c a 1 para a ou obLeíncis um C ;·: ΊΗ r jroci e Ti 3. S 1 Tí " L: Γ ' v; de lactonizai *ee ccíTt- .
BAD ORíGINAL \
As ''antaçens principais realizadas no o o iovonto con.oarodai com a arte anterior saio prosLitivids.de do orocesoo e pi.rsaã do produto ai .nsr :aiaaOs processos ar. ter'i o-,es da. arde sã.::: conduzidos num meie a 1 lamente diluído (0,1 M > a rim de n:in imi zar a TCrTaião do diíiisro. 0 presente irvsnto ps-mita a 1 acton.icação a conceri traçSes muito maiores C" õ,24r1> iselhorando assim • " *
BAD ORfG/WAL
!' aon t U ΐ. ÉiT; ífi-?r i^r- prsccsa ano a " ; c:: sdicicn ; i os ; . ·.·. :: :h:;!v5:v:í o concentrado antes de isolar a iactona; no aressrris prccai:·; a novo o cresen c& processo dssonstra urna ssaor sfl.cisrO ia a:? çuo a a-'da andarcor,
Er --“o laçado à pu.r32í do produto, o no toco da ar" te a” te!·'· j.oi" crq inoc ua 300:. — produto c qual co-n a a cia. r , >* a. a ,1. oregíduã no o Γ', n t a; o r
O II
CR urn.:;> iopurscs dioén d i f i c i 1 do rorevor, enquanto que L, ic L V 0' i 5 desta irpuracã SCO as co ndiçofic do láctr-oaíc u a :Od,r sã'- roeu o idos ir ί"?ΠΟ“· GC Qi.l·? d* , "'u * ft é alquilo:
R( d l-ò, CR-, Oh , CH^DCf^QlK^, iCCUR,, C(-0uR,K 0 H ou MH , At u u:n cati.Sc ostàli
BAD ORIGINAL
Κ — S Γ· a.'U L, _ .... ; a ;
•ί -- R. Ο F\_ S:ÍC 1 Π C ίΐ DOS'· C ΡΟ Ο Ο ;τ'; ÍL· Γ'[ 00/ 0 Η -U : . . elcui Is.
.oss;. en âquá, □ sol -senta particular á- e t er.-;u.- a :!u peias csracis--'.arisco:.: ce uúslíI :rccêcc . : . a c fêcsrcí cs o c 1 u b .i. I idade entre o scicio r sss ’ hsdrcai c a leciona.-, a c ' i s t a 1 i :: aça· s selêctccc. a soinéij.caa da. ccistslizsceo, m? íusc^c sql: j-eclvente orgânico. acetona e cetenol de preferencis ácido s ·; ? ....;, a.c o ton i t r i 1 o ou. s : i l) j Ácccp-r; :co ou. orq sn Lco cio sc i d 1 c d s d a suf iciente : ·· · · · c a : 3.1 i. z a a f.ornaçáio de una 1 ac tens. * ã;sr:plos ca êcidcs apropri.;·--.ias que poder ser sepcscsdcc ato ácido fero.ico, fccdcaicc , t r i f 1 u oro a c ético, su 1 f á r:. ca, c 1 o r i d r i c o , per c i. 6 r i c a , p -1 o 1 u s' “ ca - aLcitesuiaca e aecancsul fónica. A lactanizaçuc coda ser efaotuada ac longo de caca
ssoparâtaras d e 2 ã ° Γ a 30°C , do ort^erEncia, ·—. __·—. ror stico que a tas peradLUsa π3o suba a c .. τ r. :j>~ 30 °C Ί3 ve to crigirier is a for !T! a ·;; 0 O 0 cêêcSãse dõ Ã: L· b~D:"OdU. tO T □ o c ati.de e metálicos preferidos são catides de c"; etãiS c:a 1 inos· , ta 1 como sódio ou potássio, catives de metais a1 c a 1 i η o rrosos, tal CO;T;Q cálcio ou magnésio, ou catides de o u t r o s ga-ru.
bad original
-roais cal como: slu i r= :i, , i i ' : -rc,,sl c.j ocdelcc, Ge os iodes ae τs 00 1 ·· 1 oíl: η0 c 0- ti Rss .- rosal alcalino terroso, 0 ceco.Giês de clocvriO o:.ár p -e -Ge ri,:;-,·::.. 000: orsoaics de sódio, cálcio e e 1:.:::,:. rio se '.O Ode sT: - ; c pref cr. : - i r-\ cc
U; i i -?. i.r ;: ir· O U á O
3 de iór'medis (I - 1 - 1 d R. é CH... : J. U '
U ; :..i .4. '4 ou i , 1 111r ocj.11 o e RR 0 lH_ . s e mH s e 1· .· ·' au.ni .L ' ·*!·' solvente orpanico é doido acético, acedem: i. cri 1 o :oísÍi:ad::r ácido o ácido t d f 1 uor ::s : e d 1 fónico. Nu. m a subcle.ose R é 1 ,, 1 — d ime r í 1 cr
0.· o u á c i d o o e t a r. os··.. 1 — pilo, ·:: sol ver, te ocga-do á á ::0:0o trodooiro-
c processe do oresente o lo.το.dando: o invento
Go E:;sito1 os seoLcntea ilustram inverta s não devoo ser considerados 00 aureserdado nas Reivi.nd icacoes em enexo.
η n a f t. i 3. - 1
i
A a 3. torna DcrcS:: da água· (32 mi) foi a::::::"ací cia rente o ;;ar:rdu de 1 hora. A 00000-0 foi a ssgoo::- agitada i.aorta .0:1 2 horas, ϋ ácido t r 1 f 3. ucoocét: 1. c o foi noa ora 1 iza. d o· 001 h.i .d oi 1 ifj do ο-πο corronfrajo ' 5 :i 3 oi , 1,3o 5 ))n,; 7v rrc 3 ; o quãi foi adio sonado 1 en .taõõn -L. „ 00 arrefecoãsnt _ .!_ . - -· -'! -1 G c: o r; j a n t 0 f 0 i a seca .1 Γ " π ítj.gd c a r a p te 1 HG r 0 e r. S ca: a i. r 0 Z da. to f 0 3. d :-ajj a 1 ·? V a - 'ZZrJi |pp r, 1 . = õ-o 7; 1 s t a _£ ο 0 d 0 E-.zé t. icc-á g a a ( 1:2 v / ) sedaida por lava geo CC :T: 100 0 I da . A P ,r\ ρ ,-Ã 7 1 0 t f i ξ o ::eso conetant ILO i p· v soro .d. — — - UÍ7! imento s L‘ r< v e d 0 •r> Z C) 10 para cfrerccs 0 c on.G =:::· etc Za7 ti t a 3. ρ: C Ci IT! ..ira páreos do hSfy‘í (HPLio, o novel de dinera foi ""“•'WWf bad original \
d Ι .· ,3,6- la tj- h Ldra- Α - E 1 , 3,3 , 7,3 -, 2a ". :-- ; -Hí 3,i d r 3 (b , ò to) — d ~t. < b '> - 2 — d i oat:11 to t i ' i I a - 1 ) — i ; 9 )—o a d d 11 ]-72 7 ; 22'7 " -1 _.-o. d i.:.- i.ro - iTr-no 1 : , o 327 - hi-d··':. : r,J :,'h :;l3 3í:i-;: 2" , 7~"2- -: da:. ao.: apon - .-.vis. nustsra to ipipp. a c á t i. -r o 24 7'· olf , ;-:uj (2-:; 1 ' a 22-23 °2' ,0:1, -3.3
f;c , J õ.
Aijbp 'çr: rH; -~ - -r-o 3.S , - ; ; i } * 1 : 3,d i C 1ΟΓ, P d 3 . -l ·- bo ido dO 110-.:.:1 1 Γ ΞΡ 1 . . i .. -3 0 23... , :,-o "-Pd 0 *í - ' 3 i. -? -J10 loiõ-i-:; : · - Õ- 11V -; ‘ 7 '7 "1111.1 r ". da 00:.1:..0-.1 ,J : *: , Q ccnjun ::o "oi a. aa 3i :' a 0 1 d no io -' o 0 t 0 d hc-fr. e ;> - f-- ... 1 —' r-· "1 1 tra-dõ a I - "-oda lio -- -Po - 1 p‘;o . 7 7 ΓΠ7 13.t ....... .· „ !-1 : :.·. ido apatia õ-ap,1 (1:2 v / v > aadi i : 1 :õ- la vagem com 10ã o 1 -3 - Ãqu.a - A papo f 7 · J õ. ;*· 0 7. ·.?. a p-aao ::00 a tan da in '.'aooQ ·?. 33 °2 0 0 b u íT: v.?.rr.i.!T:9fi tO :z'J.S ,·' a da a 07 ; " -3. c bierooo ti t_ i G C G:Tí _·.(!: 3. ptp ;-e 7; a da ? — » / ; Hcd_c ; , 3 n,vei -d 0 dioaio foi
Bad origiNal
Ρrξ ρ:? r agâo de -:-:)-:2-:3(3)-:2,2-;?;€· t i 1 tat i r i 1 c:< i ) -2 ) 3 ) , i 1 R ) -2 imeti I -1,2,6,7,2 a 1 R ) — he >;ahid ron a f ti 1 — 1 í S ) j a ti 1 ’ - 4 < R ) ~r i d ro;: i--3,4,5,ò-tet^ah.id γο-2Η- p i ran-2-on a U ooopost
yUlH J J _! p t O
d D rn titula έ prspi" ma s sufa stituinde 7 — C1,2 't _o 3 ) - \ 2,2-di;net i 1 :IÍ '· ‘ "j r" X an C -5. t. O da amònio c CíTíO 8. - a;n õ Γ; t 8 acetona ou a o a t o ni cl vente orgânico, mas c ai 1. 2. w. -i L.r n a ρ r e s s r: ~ a de u:.i , / , h , H;i i R> -Meus -;: i 5 — 1 13)—na- til) — ubstsncis. a ser trilo podem e e r om um sol-. -en te a sssda da pH a
Exemplo 1 cu Enemplc 2 h i d r a-2 1S5 ,3 Fu -di met i. 1 3 í R ) , ã ( R )-d i hid rc a i hcct lac ionizada - AI terce, i iv substituídas ccmc c s neutra,, o ácida à nsutr pH 6, BAD ORIG'Mλι

Claims (2)

  1. ο ιι
    BAD ORIGINAL t r .¾ ·;; 0/" 0 r\ d ; d 0 ·' I • / 1 1 0 ? £ O tr-L< t 0? r?0H :. ·: i
    Γ: rod·.. t: j 1 r.ctona ; ι I ; ;
    (II) a.'.--: » --- · -- £ £ .£ £ .r. o - ;·- £ £ ~ 0 ' a ::'s o 0 0 0 * . - ~ — L. .. - por 1 ^ or- c:V o· : s sr rd- * : i . ; -T.?. . - Pr nassa de scaado :: c,i: a. ÍF ei vis dias £ 3. 0 J ; ι- λ·:: - ré irado pc-·· R sor' esc boi t i 1 c cl· - i i-dicsti1prop i 1 0e b — 5Pi duplas í :;.g a a des » 4b , -- Processo ds acordo C C s Reivindica t -**í 1 .Ι Car0C~ hír uuado por o ssl to PRà-Pí S 0: 1 OCO i. ? d Ο e n t =* 0 id0 0 C 0 ρic o , acet oni ά'ΐ’ο ou dcetoí. * rr; • Fr·"ar:osso ds acordo C ΟπΊ a Rei.vindaca çS o 4:. 0. 3. 0 0 0 Γ. 0 0 irado por o ca to.I isador «eido s 3 r ·_·. s 1 scc lonodo Ç?Π X. 0 0 * á.C ldu
    17 fórmico, fosfórico, trifluoroacético, sulfúrico, clorídrico, perclórico, p-toluenossulfónico e metanossulfónico.
  2. 64. - Processo de acordo com a Reivindicação 5, carac-terizado por R ser 1,1-dimetilpropilo. 7a. - Processo de acordo com a Reivindicação 6, carac-terizado por o solvente orgânico ser ácido acético e Z ser NH4+. 8a. - Processo de acordo com a Reivindicação 7, carac-terizado por o catalisador ácido ser ácido trifluoroacético, ou ácido metanossulfónico. 9a. - Processo de acordo com a Reivindicação 8, carácter izado por o catalisador ácido ser ácido metanossulfónico. 10a. - Processo de acordo com a Reivindicação 5, caracterizado por R ser sec-butilo. 11a. - Processo para a preparação de um composto de estrutura (II):
    em que (II) R é 01-10 alquilo r1 é ch3, ch2oh, ch2oc(=o)r2, co2r3, C(=0)NR4R5, OH, CH2OR2 ou CH2NR4R5; Z é H ou NH.+ ou um catião metálico; 4 R2 é C alquilo; R3 é H ou alquilo; R4 e R5 são independentemente seleccionados entre H ou alquilo; a e b são ambos ligações duplas ou um de a e b é uma ligação simples; caracterizado por compreender o tratamento de um composto de estrutura (I) 0
    em que R, R^, a e b são definidos em relação à estrutura (II) e em que Zé H, NH4+ ou um catião metálico num solvente orgânico miscível com a água, com um catalisador de ácido forte e por, em seguida, se adicionar gradualmente água até se efectuar a cristalização da lactona a partir do meio de reacção, mediante o que se produz o composto de estrutura (II) contendo menos de 0,2% de impureza dimérica. 12a. - Processo de acordo com a reivindicação 11, caracterizado por R ser C ^ alquilo, R^ ser CH3 e Z ser H ou ΝΗλ + . 4 13a. - Processo de acordo com a reivindicação 11, caracterizado por o solvente ser ácido acético, acetonitrilo ou acetona. 14a. - Processo de acordo com qualquer uma das reivindicações 11 a 13, caracterizado por Z ser NH4+. 15a. - Processo de acordo com qualquer uma das reivindicações 11 a 14, caracterizado por o catalisador de ácido forte ser ácido fórmico, fosfórico, trifluoroacético, sulfúrico, clorídrico, perclórico, p-toluenossulfónico ou metanossulfónico. 16a. - Processo de acordo com a reivindicação 11, caracterizado por se obter um composto em que R^ é CH^. 17a. - Processo de acordo com a reivindicação 11, caracterizado por se obter um composto em que R.^ é OH. 18a. - Processo de acordo com qualquer uma das reivindicações 11, 16 e 17, caracterizado por se obter um composto em que R é sec-butilo ou 1,1-dimetilpropilo e a e b serem ligações duplas. 19a. - Processo de acordo com a reivindicação 11, caracterizado por se obter a 6(R)-[2-[8(S)-2,2-dimetilbutinilo-xi)-2(S),6(R)-dimetil-1,2,6,7,8,8a(R)-hexa-hidronaftil-1(S)]- 20 etil]-4(R)-hidroxi-3,4,5,6-tetra-hidro-2H-piran-2-ona contendo menos de 0,2% de impureza dimérica. 21a. - Processo de acordo com a reivindicação 11, caracterizado por se obter a 6(R)-[2-[8(S)-(S-metilbutiriloxi)--2(S),6(R)-dimetil-1,2,6,7,8,8a(R)-hexa-hidronafti1-1(S)]etil]--4(R)-hidroxi-3,4,5,6-tetra-hidro-2H-piran-2-ona contendo menos de 0,2% de impureza dimérica. Lisboa, 17 de Julho de 1989
    J. PEREIRA DA CRUZ Agente Oficial da Propriedade Industrial RUA VtCTOR CORDON. 10 A 3.“ 1200 USBOA
PT91191A 1988-07-19 1989-07-17 Processo para a lactonizacao de acidos mevinicos e seus analogos PT91191B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/221,475 US4916239A (en) 1988-07-19 1988-07-19 Process for the lactonization of mevinic acids and analogs thereof

Publications (2)

Publication Number Publication Date
PT91191A PT91191A (pt) 1990-02-08
PT91191B true PT91191B (pt) 1995-03-01

Family

ID=22827965

Family Applications (1)

Application Number Title Priority Date Filing Date
PT91191A PT91191B (pt) 1988-07-19 1989-07-17 Processo para a lactonizacao de acidos mevinicos e seus analogos

Country Status (26)

Country Link
US (1) US4916239A (pt)
EP (1) EP0351918B1 (pt)
JP (3) JPH0273078A (pt)
KR (1) KR970011286B1 (pt)
CN (1) CN1022831C (pt)
AT (1) ATE111459T1 (pt)
AU (1) AU609319B2 (pt)
CA (1) CA1287639C (pt)
CS (1) CS274640B2 (pt)
CY (1) CY1813A (pt)
DE (1) DE68918191C5 (pt)
DK (1) DK173115B1 (pt)
ES (1) ES2058475T3 (pt)
FI (1) FI92695C (pt)
HK (1) HK136894A (pt)
HR (1) HRP930685B2 (pt)
HU (2) HU202511B (pt)
IE (1) IE64304B1 (pt)
IL (1) IL90925A (pt)
LV (1) LV11033B (pt)
NO (1) NO172800C (pt)
NZ (1) NZ229879A (pt)
PT (1) PT91191B (pt)
SI (1) SI8911362A (pt)
YU (1) YU47492B (pt)
ZA (1) ZA895458B (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
GB9007738D0 (en) * 1990-04-05 1990-06-06 British Bio Technology Compounds
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
US5250435A (en) * 1991-06-04 1993-10-05 Merck & Co., Inc. Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
AU660132B2 (en) * 1992-12-21 1995-06-08 Bayer Aktiengesellschaft Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
IN186879B (pt) * 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
IN186880B (pt) * 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
ZA9810764B (en) * 1998-04-22 1999-08-13 Ranbaxy Lab Ltd An improved process of lactonization in the preparation of statins.
CA2240983A1 (en) 1998-06-18 1999-12-18 Yong Tao Process to manufacture simvastatin and intermediates
JP4440476B2 (ja) * 1998-12-10 2010-03-24 株式会社カネカ シンバスタチンの製造方法
SK282679B6 (sk) * 1999-04-16 2002-11-06 Biotika, A. S. Spôsob izolácie lovastatínu z vyfermentovanej pôdy
SI20527A (sl) * 1999-06-29 2001-10-31 Kaneka Corporation Postopek za selektivno laktonizacijo
AU8030900A (en) * 1999-10-27 2001-05-08 Merck & Co., Inc. Lactonization process
TR200403001T3 (tr) 2000-03-03 2005-02-21 Plus Chemical, S.A. Lovastatin ve simvastatinin, azaltılmış dimerik katışkı seviyelerine sahip olacak şekilde arıtılması için bir işlem
NL1017548C2 (nl) * 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
US6797831B2 (en) * 2001-05-18 2004-09-28 Aurobindo Pharma Limited Process for lactonization to produce simvastatin
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
KR100502834B1 (ko) * 2002-03-25 2005-07-20 보령제약 주식회사 개선된 락톤화 반응에 의한 심바스타틴의 제조방법 및이의 정제방법
WO2003088900A2 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Solid forms of salts with tyrosine kinase activity
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
CA2515179A1 (en) 2003-02-11 2004-08-26 Ferenc Korodi Process for preparing simvastatin having controlled ranges of simvastatin dimer content
AU2004266740B2 (en) 2003-08-21 2010-08-26 Merck Frosst Canada Ltd Cathepsin cysteine protease inhibitors
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
ATE414071T1 (de) * 2004-03-30 2008-11-15 Lupin Ltd Verbessertes verfahren zur herstellung von 4- hydroxypyran-2-onderivaten
ATE441629T1 (de) * 2004-09-08 2009-09-15 Jubilant Organosys Ltd Verbessertes verfahren zur lactonisierung bei der herstellung von statinen
WO2006039334A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
WO2006059346A2 (en) * 2004-12-01 2006-06-08 Morepen Laboratories Limited An improved process for lactonization to produce highly pure statins
NZ555316A (en) 2004-12-09 2009-08-28 Merck & Co Inc Estrogen receptor modulators
AU2006302797B2 (en) 2005-03-02 2012-02-02 Merck Canada Inc. Composition for inhibition of cathepsin K
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
EP1741427A1 (en) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
US20070117996A1 (en) * 2005-11-21 2007-05-24 Srinivasulu Gudipati Process for preparing simvastatin
US20070142369A1 (en) * 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
MX2008008340A (es) * 2005-12-21 2008-09-03 Schering Corp Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
PE20080359A1 (es) 2006-04-19 2008-06-06 Novartis Ag Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
WO2008030382A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
ES2452349T3 (es) 2007-05-21 2014-04-01 Novartis Ag Inhibidores de CSF-1R, composiciones, y métodos de uso
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090048335A1 (en) * 2007-08-17 2009-02-19 Venkata Naga Mandava Process for preparing simvastatin
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(sarm) 및 이의 용도
CN102089016A (zh) * 2008-02-27 2011-06-08 托门医学股份公司 植入物及其制备方法
EP2204170A1 (en) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
CN101704808A (zh) 2009-11-20 2010-05-12 西南合成制药股份有限公司 制备他汀类化合物的内酯化方法
CN104098537A (zh) * 2009-11-20 2014-10-15 北大医药股份有限公司 制备他汀类化合物的内酯化方法
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
CA139852S (en) 2010-10-15 2011-11-23 Reno de Medici SpA Christmas tree
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013031729A1 (ja) 2011-08-26 2013-03-07 国立大学法人大阪大学 糖尿病性心血管合併症の予防・治療剤
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2597092A1 (en) 2011-11-24 2013-05-29 Sterling Biotech Limited A process for purification of lovastatin
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲hdm2抑制劑之經取代咪唑吡啶
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015054089A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833669A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Prmt5阻害剤
US12595248B2 (en) 2019-12-17 2026-04-07 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN115003303B (zh) 2019-12-17 2024-03-08 默沙东公司 Prmt5抑制剂
EP4673747A1 (en) 2023-03-02 2026-01-07 CARCIMUN BIOTECH GmbH Means and methods for diagnosing cancer and/or an acute inflammatory disease
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA81703B (en) * 1980-02-04 1982-09-29 Merck & Co Inc New antihypercholesterolemic compounds,intermediates and processes
JPS5948418A (ja) * 1982-09-10 1984-03-19 Sankyo Co Ltd 高血清過酸化脂質血症治療剤
US4582915A (en) * 1983-10-11 1986-04-15 Merck & Co., Inc. Process for C-methylation of 2-methylbutyrates
US4611068A (en) * 1984-11-19 1986-09-09 Merck Frosst Canada, Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
US4611067A (en) * 1985-01-31 1986-09-09 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
US4772626A (en) * 1986-01-31 1988-09-20 Merck & Co., Inc. Antihypercholesterolemic compounds
PT85109A (en) * 1986-06-23 1987-07-01 Merck & Co Inc Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors
US4857546A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof

Also Published As

Publication number Publication date
IL90925A (en) 1993-04-04
HU202511B (en) 1991-03-28
SI8911362A (en) 1997-02-28
DK354189D0 (da) 1989-07-18
NO892938L (no) 1990-01-22
LV11033B (en) 1996-06-20
FI92695C (fi) 1994-12-27
NZ229879A (en) 1991-12-23
CY1813A (en) 1995-10-20
FI92695B (fi) 1994-09-15
DE68918191T2 (de) 1995-03-02
NO892938D0 (no) 1989-07-17
ES2058475T3 (es) 1994-11-01
JPH09188672A (ja) 1997-07-22
HRP930685B1 (en) 1999-06-30
CA1287639C (en) 1991-08-13
US4916239A (en) 1990-04-10
JPH07196642A (ja) 1995-08-01
NO172800C (no) 1993-09-08
EP0351918A1 (en) 1990-01-24
DE68918191C5 (de) 2005-06-09
IE892324A1 (en) 1991-06-19
FI893363A0 (fi) 1989-07-11
EP0351918B1 (en) 1994-09-14
AU609319B2 (en) 1991-04-26
DK354189A (da) 1990-01-22
JP2718422B2 (ja) 1998-02-25
LV11033A (lv) 1996-02-20
IE64304B1 (en) 1995-07-26
HUT50804A (en) 1990-03-28
KR970011286B1 (ko) 1997-07-09
ATE111459T1 (de) 1994-09-15
KR910002828A (ko) 1991-02-26
PT91191A (pt) 1990-02-08
HRP930685B2 (hr) 2006-11-30
AU3824089A (en) 1990-01-25
IE892324L (en) 1990-01-19
CN1022831C (zh) 1993-11-24
CS274640B2 (en) 1991-09-15
CN1039420A (zh) 1990-02-07
FI893363A7 (fi) 1990-01-20
ZA895458B (en) 1990-03-28
YU47492B (sh) 1995-10-03
CS435489A2 (en) 1990-12-13
JPH0575752B2 (pt) 1993-10-21
HK136894A (en) 1994-12-09
IL90925A0 (en) 1990-02-09
YU136289A (en) 1991-02-28
DK173115B1 (da) 2000-01-31
HRP930685A2 (en) 1998-06-30
JPH0273078A (ja) 1990-03-13
HU210533A9 (en) 1995-04-28
DE68918191D1 (de) 1994-10-20
NO172800B (no) 1993-06-01

Similar Documents

Publication Publication Date Title
PT91191B (pt) Processo para a lactonizacao de acidos mevinicos e seus analogos
JP5442991B2 (ja) ジアンヒドロヘキシトールジエステル組成物の調製方法
AR020494A1 (es) Un procedimiento para la preparacion de esteres glicidilo de acidos monocarboxilicos ramificados
WO2001028996A3 (en) Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases
BR0211227A (pt) Composto, composição farmacêutica e seus usos
EP0857717B1 (en) Process for producing N-long-chain acyl acidic amino acids or salts thereof
WO2010066674A3 (de) Verfahren zur reinigung von polymethylolen
US6649775B2 (en) Process of lactonization in the preparation of statins
DK1018511T3 (da) Isochromanforbindelser og fremgangsmåde til deres fremstilling
DE10347863A1 (de) Verfahren zur Herstellung von Benzoesäureestern
AR020654A1 (es) Proceso para la recuperacion por destilacion de monoetilenglicol de alta pureza obtenido por hidrolisis de oxido de etileno
ES2173448T3 (es) Procedimiento de preparacion de esterquats (esteres con amonio cuaternario).
BR0012242A (pt) Composição de óleo para máquina de refrigeração
HRP20020730A2 (en) A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
Wimmer et al. Preparation of carbamate derivatives of 2-(4-hydroxybenzyl)-1-cyclohexanone with a juvenoid activity
Shigetomi et al. Asymmetric total synthesis of 6-tuliposide B and its biological activities against tulip pathogenic fungi
WO2001028979A3 (en) Inhibitors of neuraminidases
EA199900675A2 (ru) Полиморф моногидрата зополрестата
Hinterberger et al. Synthesis of amides from Glycosmis species: methylthiopropenoic acid, methylsulfonylpropenoic acid, thiocarbamic acid S-methyl ester, and senecioic acid amides
DE60216117T8 (de) Verfahren zur herstellung von hexafluoraceton und dessen hydrat
ES2136142T3 (es) Cristales de un compuesto antimicrobiano.
PA8469301A1 (es) Procedimientos para la preparacion de acidos hidroxamicos.
ES2170910T3 (es) Procedimiento para la preparacion de oxido de rosas.
SI21234A (sl) Postopek laktonizacije za proizvodnjo izredno čistega simvastatina
Nakamura Synthesis of (±)-gonyauline, an endogenous substance shortening the period of circadian rhythm in the unicellular alga Gonyaulax polyedra

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19940812

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20080212